Dapagliflozin & Kidney: Top 5 New Evidence Highlights in 2026 Written By ATUL SAJGURE19 Jun 2026 10:30 AM ISTChronic kidney disease (CKD) is among the most common and serious complications of type 2 diabetes (T2D), affecting nearly 32% of Indian patients...
Targeted Primary Prevention with Low-Dose Aspirin in Chronic Kidney Disease: The Predictive Role of Lipoprotein(a) Bio-Stratification- Dr Pradeep Kumar Meena Written By Dr Pradeep Kumar Meena17 Jun 2026 12:00 PM ISTA 2025 analysis of the Chronic Renal Insufficiency Cohort (CRIC) published in JACC: Advances provides a practical solution to the long-standing...
Orbit of Care in Indian T2D with CV Risk: Practice Update & Spotlight on Smart Application of Dapagliflozin & Sitagliptin FDC Written By Dr Manoj Chawla4 Jun 2026 10:56 AM ISTIn India, type 2 diabetes(T2D) clusters with cardiovascular risk and earlier age than in Western populations, mainly driven by visceral adiposity...
Dapagliflozin and Sitagliptin FDC in Indian T2D: 5 Points Clinicians May Like to Know - Dr K Baraneedharan Written By Dr. K. Baraneedharan9 April 2026 12:00 PM ISTThe burden of T2DM is increasing worldwide, with enormous implications for morbidity and mortality. Early and effective intervention is essential to...
Robust Glycemic Control & Cardio-Renal Protection: Meeting the Advanced Needs of Indian Uncontrolled T2D with Empagliflozin, Sitagliptin, Metformin Written By Dr. Nilanjan Sengupta28 Jan 2026 12:45 PM ISTIndia has an estimated 90 million people living with T2D [1] amid rising obesity and doubled management costs. Uncontrolled T2DM and early-onset...
Optimising Type 2 Diabetes Outcomes through Dapagliflozin and Sitagliptin FDC: A Gluco-Cardio-Renal Perspective Written By Dr. Mayur Agrawal27 Nov 2025 11:15 AM ISTType 2 Diabetes (T2D) is a major public health challenge, with India ranking second globally in prevalence. [1] The coexistence of diabetes,...
Penicillin-Binding Protein 3 Inserts in E.coli:A Growing Burden of Underreported Threat Dr. Kamal Kant Kohli31 July 2025 11:02 AM ISTIntroductionPenicillin-binding proteins (PBPs) synthesize and remodel the peptidoglycan layer of the bacterial cell wall, which maintain cell shape...
Uncontrolled T2D in India: Valuable Consideration for Dapagliflozin Sitagliptin Combination Dr. D.C. Sharma25 July 2025 12:11 PM ISTIndia accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India are living with diabetes,...
Beyond BMI: Why Pioglitazone Deserves a Place in Managing 'Thin-Fat' Type 2 Diabetes in India Written By Dr. Kaushik Pandit26 Jun 2025 11:03 AM ISTThin-Fat Paradox in Indian T2DM - A Distinct Metabolic Challenge: In the Indian population, the 'thin-fat' phenotype-normal BMI with excess visceral...
Prediabetes and CKD: An Overlooked Interaction in Early Metabolic Disease Dr. Gayatri S11 Jun 2025 11:06 AM ISTPrediabetes and CKD: A Growing Double BurdenThe rising prevalence of prediabetes and chronic kidney disease (CKD) in India reflects an...
Relevance of Pioglitazone in Indian T2DM Care Continuum Dr. Vijay Panikar27 May 2025 11:30 AM ISTIndia is experiencing a rising burden of type 2 diabetes (T2D), affecting 11.4% of adults. Hypertension (35.5%), generalized obesity (28.6%),...
Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases Written By Dr. Sanjay Mittal14 May 2025 11:37 AM ISTCardiovascular diseases (CVD) account for 24.8% of all deaths in India, with an age-standardized death rate of 272 per 100,000-higher than the global...
